This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Nov;32(9):1205-6; author reply 1206-7.

doi: 10.1111/j.1365-2036.2010.04451.x.

Reporting of relapse rates in a trial of mesalazine for ulcerative colitis

A C Ford

PMID: 21039682
DOI: 10.1111/j.1365-2036.2010.04451.x

Comment

Reporting of relapse rates in a trial of mesalazine for ulcerative colitis

A C Ford. Aliment Pharmacol Ther. 2010 Nov.

. 2010 Nov;32(9):1205-6; author reply 1206-7.

doi: 10.1111/j.1365-2036.2010.04451.x.

Author

A C Ford

PMID: 21039682
DOI: 10.1111/j.1365-2036.2010.04451.x

No abstract available

PubMed Disclaimer

Comment on

Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial.
Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Merchant K, Shaw A, Bortey E, Forbes WP. Lichtenstein GR, et al. Aliment Pharmacol Ther. 2010 Oct;32(8):990-9. doi: 10.1111/j.1365-2036.2010.04438.x. Epub 2010 Aug 18. Aliment Pharmacol Ther. 2010. PMID: 20937044 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information